{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:56:53Z","timestamp":1778810213981,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ygyno.2011.05.022","type":"journal-article","created":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T00:10:29Z","timestamp":1309047029000},"page":"527-531","source":"Crossref","is-referenced-by-count":11,"title":["Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer"],"prefix":"10.1016","volume":"122","author":[{"given":"Lisa M.","family":"Landrum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Johnny","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Scott","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2011.05.022_bb0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ygyno.2011.05.022_bb0010","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ygyno.2011.05.022_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.022_bb0020","series-title":"NCI Clinical Announcement: intraperitoneal chemotherapy for ovarian cancer","year":"2006"},{"issue":"11","key":"10.1016\/j.ygyno.2011.05.022_bb0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jnci\/djp151","article-title":"Intraperitoneal therapy for ovarian cancer: why has it not become standard?","volume":"101","author":"Rowan","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ygyno.2011.05.022_bb0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1634\/theoncologist.2007-0224","article-title":"Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view","volume":"13","author":"Vergote","year":"2008","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ygyno.2011.05.022_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.05.022_bb0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1996.0210","article-title":"Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity","volume":"62","author":"Connelly","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ygyno.2011.05.022_bb0045","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ygyno.2011.05.022_bb0050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/IGC.0b013e3181b33d5b","article-title":"Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer","volume":"19","author":"Seamon","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2011.05.022_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2008.12.035","article-title":"An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer","volume":"113","author":"Berry","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.05.022_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2008.11.021","article-title":"Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma","volume":"112","author":"Chin","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2011.05.022_bb0065","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2011.05.022_bb0070","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.mcna.2010.03.002","article-title":"The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization","volume":"94","author":"Pagani","year":"2010","journal-title":"Med Clin North Am"},{"issue":"6","key":"10.1016\/j.ygyno.2011.05.022_bb0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2006.10.077","article-title":"Relationship between cisplatin administration and the development of ototoxicity","volume":"24","author":"Rademaker-Lakhai","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2011.05.022_bb0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1525-1438.2007.00940.x","article-title":"Ototoxicity after intraperitoneal chemotherapy: a case report","volume":"17","author":"Nieves","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2011.05.022_bb0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/gyno.2000.6108","article-title":"Complications associated with intraperitoneal chemotherapy catheters","volume":"81","author":"Makhija","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2011.05.022_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001703-199901000-00005","article-title":"Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma","volume":"11","author":"Makhija","year":"1999","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.05.022_bb0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2009.11.009","article-title":"Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications","volume":"116","author":"Lesnock","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.05.022_bb0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2007.10.004","article-title":"Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates","volume":"108","author":"Landrum","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.05.022_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0090-8258(91)90266-8","article-title":"Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system","volume":"41","author":"Davidson","year":"1991","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.05.022_bb0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ygyno.2009.01.007","article-title":"Intraperitoneal chemotherapy for ovarian cancer: 2009 goals","volume":"112","author":"Walker","year":"2009","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811004197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811004197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T10:19:31Z","timestamp":1560334771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811004197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0090825811004197"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}